Uppsala, Sweden

Jimmy Hedin Dahlström

This inventor holds 1 USPTO granted patent and 3 EPO patents. Top assignee: Cytiva Bioprocess R&d Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jimmy Hedin Dahlström. Retrieved from https://idiyas.com/inventor/jimmy-hedin-dahlström

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jimmy Hedin Dahlström: Innovator in Separation Technologies

Introduction

Jimmy Hedin Dahlström is an inventor based in Uppsala, Sweden. He has made significant contributions to the field of separation technologies, particularly through his work with various companies. Notably, he has been associated with Puridify Ltd. and GE Healthcare Bio-Sciences AB. Although he currently holds no granted patents, his innovative ideas are reflected in his patent applications.

Latest Patent Applications

One of Jimmy Hedin Dahlström's notable patent applications is titled "Separation Matrix and Method of Separation." This invention discloses a separation matrix comprising a plurality of multimodal ligands covalently coupled to a support. The support is a membrane made of nonwoven polymer fibers, and the ligands are designed to interact with target biomacromolecules. Additionally, the invention outlines separation methods utilizing this separation matrix.

Conclusion

Jimmy Hedin Dahlström is a promising inventor whose work in separation technologies showcases his innovative spirit. His contributions, although not yet reflected in granted patents, indicate a strong potential for future advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…